Leucogen Tablets at 60 mg Three Times per Day are Safe and Effective to Control Febrile Neutropenia |
Huang, Xin-En
(Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
Cao, Jie (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) Qian, Zhi-Ying (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) Xu, Xia (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) Shi, Lin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) Wu, Xue-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) Liu, Jin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) Wang, Lin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) |
1 | Kozma CDM, Chia V, Legg L, et al (2012). Trends in Neutropenia-Related Inpatient Events. J Oncol Pract, 8 (3):149-55. DOI |
2 | Liu J, Huang XE, Tian GY, et al (2013). Phase II Study on safety and efficacy of Yadanzi (Javanica oil emulsion injection) combined with chemotherapy for patients with gastric cancer. Asian Pac J Cancer Prev, 14, 2009-12. DOI ScienceOn |
3 | Lyman GH, Kuderer NM (2002). Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs, 62, 65-78. DOI |
4 | Lyman GH, Lyman CH, Agboola O (2005). Risk models for predicting chemotherapy-induced neutropenia. Oncologist, 10, 427-37. DOI |
5 | Miller AB, Hoogstraten B, Staquet M, et al (1981). Reporting results of cancer treatment. Cancer, 47, 207-14. DOI ScienceOn |
6 | Morrison VA, Wong M, Hershman D, et al (2007). Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm, 13, 337-48. |
7 | NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. |
8 | Schilling MBPC, Deeter RG (2011). Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med, 2, 859-66. |
9 | Tan HTK, Hurley D, Daniel G, et al (2011). Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin, 27, 79-6. DOI |
10 | Weycker D, Malin J, Glass A, et al (2007). Economic burden of chemotherapy-related febrile neutropenia. J Support Oncol, 5, 44-5. |
11 | Weycker DMJ, Barron R, Edelsberg J, et al (2011). Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol, 35, 267-74. |
12 | Yan HA, Shen K, Huang XE (2013). Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4801-4. DOI ScienceOn |
13 | Zhan YP, Huang XE, Cao J, et al (2012). Clinical study on safety and efficacy of Qinin (Cantharidin Sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 4773-6. DOI ScienceOn |
14 | Caggiano V, Weiss RV, Rickert TS, et al (2005). Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer, 103, 1916-24. DOI |
15 | Crawford J, Dale DC, Lyman GH (2004). Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer, 100, 228-37. DOI ScienceOn |
16 | Lyman GH, Kuderer N, Greene J, Balducci L (1998). The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer, 34, 1857-64. DOI |
17 | Kuderer NM, Dale DC, Crawford J, et al (2006). Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 106, 2258-66. DOI ScienceOn |